SG ISSUER/CALL/WUXI BIOLOGICS (CAYMAN)/58.63/0.02/24.07.24

SG ISSUER/CALL/WUXI BIOLOGICS (CAYMAN)/58.63/0.02/24.07.24 Stock

17933

HK0000692811

Delayed Hong Kong S.E. 04:00:00 2024-07-11 am EDT
0.01 ^HKD	0.00%

Current year

-9.09%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart WUXI BIOLOGICS (CAYMAN) INC.

Chart SG ISSUER/CALL/WUXI BIOLOGICS (CAYMAN)/58.63/0.02/24.07.24

Latest news about WUXI BIOLOGICS (CAYMAN) INC.

CANbridge Announces Last Patient Last Visit in CAN103 Phase 2/Registration Trial for Gaucher Disease	Jul. 09	AQ
Bank of China Downgrades Wuxi Biologics (Cayman) to Hold From Buy, Price Target is HK$14	Jun. 27	MT
Wuxi Biologics Terms US Plant's Expansion Halt as Normal Business Adjustment	Jun. 19	MT
WuXi Biologics Named to MSCI ESG Leaders Indexes for Second Consecutive Year	Jun. 17	AQ

More news

Quotes 5-day view

Date	Price	Change
24-07-11	0.01	0.00%
24-07-10	0.01	0.00%
24-07-09	0.01	0.00%
24-07-08	0.01	0.00%
24-07-05	0.01	0.00%

Delayed Quote Hong Kong S.E.

Last update July 11, 2024 at 04:00 am EDT

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	WUXI BIOLOGICS (CAYMAN) INC.
Issuer	Société Générale
	17933
ISIN	HK0000692811
Date issued	2023-06-20
Strike	58.63 $
Maturity	2024-07-24 (13 Days)
Parity	50 : 1
Emission price	0.15 $
Emission volume	N/A
Settlement	cash
Currency	HKD

Technical Indicators

Highest since issue	0.144 $
Lowest since issue	0.01 $
Spread	- $
Spread %	-.--%

Company Profile

WuXi Biologics (Cayman) Inc is an investment holding company principally engaged in the provision of end-to-end solutions and services for biologics discovery, development and manufacturing to customers involving in biologics industry. The Company mainly operates its business through two segments. The Biologics segment mainly engages in the provision of biologics discovery, development and manufacturing. The WuXi XDC (XDC) segment mainly engages in the provision of contract research, development and manufacturing organization (CRDMO) services for antibody-drug conjugate (ADCs) and various bioconjugates. The Company mainly conducts its business in the domestic and overseas markets.

Sector

More about the company

Ratings for WuXi Biologics (Cayman) Inc.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Consensus: WuXi Biologics (Cayman) Inc.

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

10.34 CNY

Average target price

20.93 CNY

Spread / Average Target

+102.48%

Consensus